IDEXX Laboratories, Inc. - Common Stock (IDXX)
524.18
-1.75 (-0.33%)
NASDAQ · Last Trade: Jun 11th, 5:15 PM EDT
Detailed Quote
Previous Close | 525.93 |
---|---|
Open | 526.31 |
Bid | 520.00 |
Ask | 527.00 |
Day's Range | 520.88 - 528.38 |
52 Week Range | 356.14 - 530.73 |
Volume | 374,014 |
Market Cap | 44.60B |
PE Ratio (TTM) | 48.45 |
EPS (TTM) | 10.8 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 540,815 |
Chart
About IDEXX Laboratories, Inc. - Common Stock (IDXX)
Idexx Laboratories is a global leader in veterinary diagnostics, providing a wide range of innovative products and services that enhance animal health and well-being. The company develops and manufactures diagnostic tests and equipment for companion animals, livestock, and poultry, helping veterinarians and livestock producers make informed health decisions. Additionally, Idexx offers various software solutions for practice management and laboratory information, along with water testing services to ensure public safety and environmental protection. With a commitment to advancing veterinary medicine and improving animal care, Idexx plays a crucial role in the healthcare ecosystem for animals and the people who care for them. Read More
News & Press Releases
Via Benzinga · June 11, 2025
A mix of bullish catalysts lifts investor sentiment as Trump confirms trade deal with China and May inflation data comes in softer than expected.
Via Benzinga · June 11, 2025
Three U.S. lawmakers have disclosed recent purchases of a pet healthcare company just weeks before supporting a biotech bill.
Via Benzinga · June 11, 2025

IDEXX Laboratories (IDXX) is a high-quality stock with strong revenue growth, exceptional profitability, and solid financial health, making it a compelling pick for long-term investors.
Via Chartmill · June 2, 2025
Via Benzinga · May 26, 2025
Via Benzinga · May 21, 2025
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT).
By IDEXX Laboratories, Inc. · Via Business Wire · May 13, 2025
A fundamental analysis of (NASDAQ:IDXX): Why NASDAQ:IDXX Stands Out as a Quality Stock.
Via Chartmill · May 7, 2025
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · May 1, 2025
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · May 1, 2025
The company has adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.
Via Stocktwits · May 1, 2025
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · May 1, 2025
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results.
By IDEXX Laboratories, Inc. · Via Business Wire · May 1, 2025
Via Benzinga · April 29, 2025
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
By IDEXX Laboratories, Inc. · Via Business Wire · April 3, 2025
Via The Motley Fool · March 29, 2025

Every stock tells a story; it takes humans to find the meaning in it.
Via The Motley Fool · February 19, 2025

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:
By IDEXX Laboratories, Inc. · Via Business Wire · February 13, 2025

Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments.
Via The Motley Fool · February 3, 2025